Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation. 45th Annual Meeting and Exhibition of the American-Society-of-Hematology Gotlib, J., Berube, C., Ruan, J., Growney, J., Dugan, K., Falkow, R., Rosamilia, M., Resta, D., Cohen, P., Fabbro, D., Heinrich, M., Gilliland, D. G., Coutre, S. AMER SOC HEMATOLOGY. 2003: 919A–919A
View details for Web of Science ID 000186536703420